BergerTRubnerPSchautzerF, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med2003; 349(2): 139–145.
2.
KuhleJPohlCMehlingM, et al. Lack of association between antimyelin antibodies and progression to multiple sclerosis. N Engl J Med2007; 356: 371–378.
3.
O’ConnorKCMcLaughlinKADe JagerPL, et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nature Medicine2007; 13: 211–217.
4.
KitleyJWatersPWoodhallM, et al. Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: A comparative study. JAMA Neurol2014; 71(3): 276–283.
5.
SatoDKCallegaroDLana-PeixotoMA, et al. Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology2014; 82: 474–481.
JurynczykMMessinaSWoodhallMR, et al. Clinical presentation and prognosis in MOG-antibody disease: A UK study. Brain2017; 140(12): 3128–3138.
8.
OliveiraLMApostolos-PereiraSLPitombeiraMS, et al. Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis. Mult Scler2019; 25: 1907–1914.
9.
WildemannBJariusSSchwarzA, et al. Failure of alemtuzumab therapy to control MOG encephalomyelitis. Neurology2017; 89(2): 207–209.
10.
DosPassosGROliveiraLMda CostaBK, et al. MOG-IgG-associated optic neuritis, encephalitis, and myelitis: Lessons learned from neuromyelitis optica spectrum disorder. Front Neurol2018; 9: 217.
